EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A chimeric anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy

Brian C Gilger, Tomoko Hasegawa, R Bryan Sutton, Jacquelyn J Bower, Chengwen Li, Matthew L Hirsch

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Brian C Gilger und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, North Carolina State University, Raleigh, NC 27607, USA; Bedrock Therapeutics, Raleigh, NC 27613, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Corneal Transplantation, Graft Rejection, Dependovirus. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Eye Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Corneal blindness affects more than 5 million individuals, with over 180,000 corneal transplantations (CTs) performed annually. In high-risk CTs, almost all grafts are rejected within 10 years. Here, we investigated adeno-associated virus (AAV) ex vivo gene therapy to establish immune tolerance in the corneal allograft to prevent high-risk CT rejection. Our previous work has demonstrated that HLA-G contributes to ocular immune privilege by inhibiting both immune cells and neovascularization; however, homodimerization is a rate-limiting step for optimal HLA-G function. Therefore, a chimeric protein called single-chain immunomodulator (scIM), was engineered to mimic the native activity of the secreted HLA-G dimer complex and eliminate the need for homodimerization. In a murine corneal burn model, AAV8-scIM significantly reduced corneal vascularization and fibrosis. Next, ex vivo AAV8-scIM gene delivery to corneal allografts was evaluated in a high-risk CT rejection rabbit model. All scIM-treated corneas were well tolerated and transparent after 42 days, while 83% of vehicle-treated corneas were rejected. Histologically, AAV-scIM-treated corneas were devoid of immune cell infiltration and vascularization, with minimal fibrosis at the host-graft interface. The data collectively demonstrate that scIM gene therapy prevents corneal neovascularization, reduces trauma-induced corneal fibrosis, and prevents allogeneic CT rejection in a high-risk large animal model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyCorneal TransplantationGraft RejectionDependovirusDisease Models, AnimalAnimalsMiceRabbitsGenetic VectorsHumansImmunologic FactorsCorneal NeovascularizationCornea

Stichwörter der Autor:innen

AAV gene therapyHLA-Gcorneal transplant rejectionfibrosisimmune suppressionimmunomodulationinflammationneovascularizationscIMsingle chain immunomodulator

Substanzen

Immunologic Factors

Autor:innen und Institutionen

  • Department of Clinical Sciences, North Carolina State University, Raleigh, NC 27607, USA; Bedrock Therapeutics, Raleigh, NC 27613, USA.
  • Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Bedrock Therapeutics, Raleigh, NC 27613, USA.
  • Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
  • Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Bedrock Therapeutics, Rale…
  • Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Bedrock Therapeutics, R…

Förderung

  • NIDDK NIH HHS
  • National Eye Institute
  • National Institutes of Health
  • University of North Carolina

Zitieren

APA

Gilger, B. C., Hasegawa, T., Sutton, R. B., Bower, J. J., Li, C., & Hirsch, M. L. (2024). A chimeric anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.09.007

Vancouver

Gilger BC, Hasegawa T, Sutton RB, Bower JJ, Li C, Hirsch ML. A chimeric anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.09.007

BibTeX
@article{Gilger2024,
  author = {Gilger, Brian C and Hasegawa, Tomoko and Sutton, R Bryan and Bower, Jacquelyn J and Li, Chengwen and Hirsch, Matthew L},
  title = {A chimeric anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.09.007}
}
Kostenlos starten →